mRNA vaccination using peptide nanoparticles triggers a strong immune response against endogenous GPC2 in a murine neuroblastoma model.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Neuroblastoma is an aggressive pediatric solid tumor that arises during embryonic development and contributes to 15% of cancer-related deaths in children. To date, neither experimental nor clinical trial data on an mRNA vaccine for neuroblastoma have been published, highlighting a significant gap in the anticancer vaccine development pipeline. This study presents the first mRNA vaccine for the treatment of neuroblastoma. We explored the self-assembling peptide RALA for delivering mRNA encoding glypican 2 (GPC2), a potent tumor-associated antigen in neuroblastoma. These data outline rigorous in vitro characterization of vaccine nanoparticle formulations, cellular uptake, and functionality. Immunization of mice with RALA/mGPC2 generated an antigen-specific cellular immune response against GPC2, with significant increases in IFN-γ and IL-2 expression by splenocytes and TNF-α expression by CD4+ and CD8+ T cells. Immunization delayed tumor development by 10-11 days and reduced tumor volume by 70% compared with unvaccinated controls in a subcutaneous murine model of MYCN-amplified neuroblastoma. This work demonstrates the therapeutic potential of the RALA/mGPC2 vaccine for treating neuroblastoma. Additionally, GPC2 is upregulated across multiple adult and pediatric cancer subtypes, establishing this vaccine as an attractive immunotherapy with far-reaching potential.